408 results
Page 13 of 21
6-K
EX-99.1
l0a0zm
17 Aug 12
Teva Announces Launch of Generic ACTOplusmet® in the United States
12:00am
6-K
EX-99.1
5tpnbl
17 Aug 12
Teva Announces Launch of Generic Actos® in the United States
12:00am
6-K
38h6u1gpcn
8 Aug 12
Current report (foreign)
12:00am
6-K
EX-99.1
d76413jtj
8 Aug 12
Teva to Initiate Third Phase Iii Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis
12:00am
6-K
EX-99.1
mo4ib2vyhnazzx8ii90f
6 Aug 12
Teva Reports Second Quarter 2012 Results
12:00am
6-K
nbwquuzx
2 Aug 12
Current report (foreign)
12:00am
6-K
EX-99.1
bkzxpn8dzl5y
2 Jul 12
Teva Announces Progress of Biologic Investigational Drugs Evaluated to Treat Neutropenia In Breast Cancer Patients Undergoing Chemotherapy
12:00am
6-K
EX-99.1
1cyj35c129em89 c368i
21 Jun 12
Teva Announces Launch of Generic Symbyax® in the United States
12:00am
6-K
EX-99.1
8uo5zda6cfjbkp5r 0qh
19 Jun 12
More Than 15 Clinical, Pre-Clinical and Health Economics Studies Will Be Presented
12:00am
6-K
EX-99.1
d2s0 r7331
19 Jun 12
Live Filing
12:00am
6-K
EX-99.1
q2edh w4fhmi
1 Jun 12
Teva Pharmaceutical Industries Ltd. Chairman of the Board Dr. Phillip Frost Purchases 1 Million Teva Shares
12:00am
6-K
EX-99.1
xz0lx3
24 May 12
Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40
12:00am
6-K
EX-99.1
8kv4v65ke3rctg336r
23 May 12
Live Filing
12:00am
6-K
EX-99.1
f91hx uq3
17 May 12
Teva’s Board of Directors Votes to Re-Elect Dr. Phillip Frost as Chairman of the Board
12:00am
6-K
pv1bw7s ri2nr7dt9f
9 May 12
Teva Pharmaceutical Industries Limited 6-K
12:00am
6-K
EX-2.1
g9tdpn5ng9o e4s71z
9 May 12
Current report (foreign)
12:00am
6-K
laqiw5
9 May 12
Current report (foreign)
12:00am
6-K
EX-99.1
y76k3nhkduxf4rn7t6hn
8 May 12
Teva Appoints Michael Hayden as President of Global Research and Development and Chief Scientific Officer
12:00am
6-K
EX-99.1
8mal0rx m4w
1 May 12
Live Filing
12:00am
6-K
EX-99.1
ipd l39kq
27 Apr 12
Live Filing
12:00am